CXCR2 and neoplasm: Recently, it has been shown that following the ligation of these chemokines, such as CXCL1 to CXCR2, tumor-associated immune cells can recruit into the tumor milieu to suppress anti-tumor immune responses and also activate the angiogenic processes [39].